Literature DB >> 28236265

The longitudinal course of depression symptomatology following a palliative rehabilitation program.

Andrea Feldstain1,2,3, Sophie Lebel4, Martin R Chasen5,6,7.   

Abstract

PURPOSE: Patients with advanced cancer have increased life expectancy but suffer from ongoing burden. Depressive symptomatology is their most common mental health concern. The Ottawa Palliative Rehabilitation Program (PRP) offers rehabilitation for this population. It offers 8 weeks of individualized interdisciplinary rehabilitation, post cancer treatment. Interventions include medical (physician and nurse), physiotherapy, occupational therapy, dietary, and social work using a general self-efficacy framework. Pilot data suggest benefits in a range of domains, including ratings of feeling "depressed." We examined whether reduced symptomatology was maintained 3 months after PRP completion.
METHODS: Participants with advanced heterogeneous cancers who completed the PRP were mailed the Hospital Anxiety and Depression Scale (among others) 3-month post-PRP (n = 44). Demographic and medical information were obtained from patient files.
RESULTS: There was a significant linear trend (mean T1: 6.79 ± 2.29; T2: 5.23 ± 3.06; T3: 4.59 ± 3.34; p = 0.007) with statistically and clinically significant decreases in reported depressive symptomatology between T1 and T2 (p = 0.042) and T1 and T3 (p = 0.007). There was a significant decreases in number of cases reporting symptomatology scores in the clinical range from T1 to T3 (p = 0.038).
CONCLUSION: Patients who undergo a palliative rehabilitation program may experience relief of mild depressive symptomatology, maintainable 3-month post-PRP. The sample was exhibiting mild symptomatology and these results may not be generalizable to those with higher scores; a lack of specialized psychosocial clinician may have affected the acquired sample. Experimental designs are needed to more thoroughly compare these findings to independent rehabilitation interventions.

Entities:  

Keywords:  Advanced cancer; Depression; Interdisciplinary intervention; Palliative care; Rehabilitation

Mesh:

Year:  2017        PMID: 28236265     DOI: 10.1007/s11136-017-1531-7

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  33 in total

Review 1.  Advanced cancer: emergence of a new survivor population.

Authors:  Pamela J Haylock
Journal:  Semin Oncol Nurs       Date:  2010-08       Impact factor: 2.315

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

Review 3.  A review and recommendations for optimal outcome measures of anxiety, depression and general distress in studies evaluating psychosocial interventions for English-speaking adults with heterogeneous cancer diagnoses.

Authors:  Tim Luckett; Phyllis N Butow; Madeleine T King; Mayumi Oguchi; Gaynor Heading; Nadine A Hackl; Nicole Rankin; Melanie A Price
Journal:  Support Care Cancer       Date:  2010-07-02       Impact factor: 3.603

4.  Self-efficacy: toward a unifying theory of behavioral change.

Authors:  A Bandura
Journal:  Psychol Rev       Date:  1977-03       Impact factor: 8.934

5.  Minor versus major depression: a comparative clinical study.

Authors:  Jean M Fils; Elizabeth C Penick; Elizabeth J Nickel; Ekkehard Othmer; Cherilyn Desouza; William F Gabrielli; Edward E Hunter
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

6.  Diagnostic validity of the Hospital Anxiety and Depression Scale (HADS) in cancer and palliative settings: a meta-analysis.

Authors:  Alex J Mitchell; Nick Meader; Paul Symonds
Journal:  J Affect Disord       Date:  2010-03-05       Impact factor: 4.839

7.  Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies.

Authors:  Alex J Mitchell; Melissa Chan; Henna Bhatti; Marie Halton; Luigi Grassi; Christoffer Johansen; Nicholas Meader
Journal:  Lancet Oncol       Date:  2011-01-19       Impact factor: 41.316

Review 8.  Exercise for depression.

Authors:  Gillian E Mead; Wendy Morley; Paul Campbell; Carolyn A Greig; Marion McMurdo; Debbie A Lawlor
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

9.  Ten-year survival in patients with metastatic prostate cancer.

Authors:  Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario Eisenberger; Maha Hussain
Journal:  Clin Prostate Cancer       Date:  2003-06

10.  An interdisciplinary palliative rehabilitation intervention bolstering general self-efficacy to attenuate symptoms of depression in patients living with advanced cancer.

Authors:  A Feldstain; S Lebel; M R Chasen
Journal:  Support Care Cancer       Date:  2015-05-08       Impact factor: 3.603

View more
  3 in total

1.  A little help from my friends: social support in palliative rehabilitation.

Authors:  N A Rutkowski; S Lebel; K Richardson; B Mutsaers; M Chasen; A Feldstain
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

2.  Combined exercise and nutritional rehabilitation in outpatients with incurable cancer: a systematic review.

Authors:  Charlie C Hall; Jane Cook; Matthew Maddocks; Richard J E Skipworth; Marie Fallon; Barry J Laird
Journal:  Support Care Cancer       Date:  2019-04-03       Impact factor: 3.603

3.  A randomised, phase II, unblinded trial of an Exercise and Nutrition-based Rehabilitation programme (ENeRgy) versus standard care in patients with cancer: feasibility trial protocol.

Authors:  Marie Fallon; Barry J Laird; Charlie C Hall; Lucy Norris; Liz Dixon; Jane Cook; Matthew Maddocks; Catriona Graham; Sharon Tuck; Erna Haraldsdottir; Duncan Brown; Anna Lloyd; Anne Finucane; Peter Hall; Katharina Diernberger; Richard J E Skipworth
Journal:  Pilot Feasibility Stud       Date:  2018-12-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.